Scilex Holding (SCLXW) Depreciation & Amortization (CF) (2022 - 2026)

Scilex Holding (SCLXW) recorded quarterly Depreciation & Amortization (CF) of $2.9 million in Q1 2026, up 80.78% quarter-over-quarter from $1.6 million in Q4 2025, and up 186.04% on a YoY basis from $1.0 million in Q1 2025.

Scilex Holding (SCLXW) Depreciation & Amortization (CF) (2022 - 2026) Analysis & Trends

Scilex Holding's Depreciation & Amortization (CF) history runs 5 years deep, the most recent figure standing at $2.9 million for Q1 2026.

  • In Q1 2026, Depreciation & Amortization (CF) rose 186.04% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $6.5 million (up 61.5% YoY), while the FY2025 annual figure was $4.6 million, up 14.26% from the prior year.
  • Depreciation & Amortization (CF) was $2.9 million for Q1 2026 at Scilex Holding, up from $1.6 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $2.9 million in Q1 2026 to a low of $944000.0 in Q1 2022.
  • Historically, Depreciation & Amortization (CF) has averaged $1.2 million across 5 years, with a median of $1.0 million in 2024.
  • The sharpest annual moves came in 2024 and 2026: Depreciation & Amortization (CF) fell 3.27% in 2024, then soared 186.04% in 2026.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $1.0 million in 2022, then decreased by 0.1% to $1.0 million in 2023, then slipped by 2.9% to $1.0 million in 2024, then surged by 58.07% to $1.6 million in 2025, then surged by 80.78% to $2.9 million in 2026.
  • The last three Depreciation & Amortization (CF) figures came in at $2.9 million (Q1 2026), $1.6 million (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Depreciation & Amortization (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn -
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn 509.00 Mn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn 2.00 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn 188.00 Mn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn 581.00 Mn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn 1.12 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn 93.00 Mn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn 1.61 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn 594.00 Mn
10 Scilex Holding - - 4.15 Mn 2.87 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 2.87 Mn
Mar 31, 2026 2.87 Mn
Dec 31, 2025 1.59 Mn
Dec 31, 2025 1.59 Mn
Sep 30, 2025 1.02 Mn
Sep 30, 2025 1.02 Mn
Jun 30, 2025 1.01 Mn
Jun 30, 2025 1.01 Mn
Mar 31, 2025 1.00 Mn
Mar 31, 2025 1.00 Mn
Dec 31, 2024 1.00 Mn
Dec 31, 2024 1.00 Mn
Sep 30, 2024 1.01 Mn
Sep 30, 2024 1.01 Mn
Jun 30, 2024 1.01 Mn
Jun 30, 2024 1.01 Mn
Mar 31, 2024 1.03 Mn
Mar 31, 2024 1.03 Mn
Dec 31, 2023 1.03 Mn
Dec 31, 2023 1.03 Mn